LILRB5/CD85c/LIR-8[Biotin], His & Avi, Human

LILRB5/CD85c/LIR-8[Biotin], His & Avi, Human

LILRB5, also known as CD85c andLIR-8, belongs to a family of transmembrane glycoproteins that negatively regulate immune cell activation. Mature human LIR-8 consists of a 435 amino acid (aa) extracellular domain with four Ig-like domains, a 21 aa transmembrane segment, and a 111 aa cytoplasmic domain with two immunoreceptor tyrosine-based inhibitory motifs (ITIM). LILRB5 may act as receptor for class I MHC antigens.
Z04548
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
LILRB5/CD85c/LIR-8 (Arg18-His456)
Accession # O75023-1		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 49.9 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 65-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background LILRB5, also known as CD85c andLIR-8, belongs to a family of transmembrane glycoproteins that negatively regulate immune cell activation. Mature human LIR-8 consists of a 435 amino acid (aa) extracellular domain with four Ig-like domains, a 21 aa transmembrane segment, and a 111 aa cytoplasmic domain with two immunoreceptor tyrosine-based inhibitory motifs (ITIM). LILRB5 may act as receptor for class I MHC antigens.
Synonyms CD85C ; LIR-8; LIR8

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.